Norge - norsk - Statens legemiddelverk

abbvie as - deoksykolsyre - injeksjonsvæske, oppløsning - 10 mg/ ml

Norge - norsk - Statens legemiddelverk

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 11.25 mg

Norge - norsk - Statens legemiddelverk

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

Norge - norsk - Statens legemiddelverk

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 30 mg

Norge - norsk - Statens legemiddelverk

abbvie as - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning

Den europeiske union - norsk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Den europeiske union - norsk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migrene lidelser - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Norge - norsk - Statens legemiddelverk

abbvie as - foslevodopa / foskarbidopa - infusjonsvæske, oppløsning - 240 mg/ ml / 12 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridement - preparater for behandling av sår og sår - nexobrid er indikert for fjerning av eschar hos voksne med dype partielle og fullverdige termiske forbrenninger.

Den europeiske union - norsk - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - bukspyttkjertelblodsykdommer - antineoplastiske midler - behandling av metastatisk adenocarcinoma av bukspyttkjertelen, sammen med 5 fluorouracil (5 fu) og leucovorin (lv), i voksen pasienter som har kommet etter gemcitabine basert terapi.